key: cord-0744226-z4avm4zp
authors: de Llano, Luis A. Pérez; Golpe, Rafael; Pérez-Ortiz, Diego; Menéndez, Rosario; Yandiola, Pedro P España; Artaraz, Amaia; Zalacain, Rafael; Cilloniz, Catia; Torres, Antoni
title: El inicio temprano de corticosteroides podría ser perjudicial en pacientes hospitalizados con neumonía COVID-19: un estudio multicéntrico mediante índice de propensión
date: 2021-10-24
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2021.10.001
sha: 8779a86c08601420348c5bb20bceff505654b9de
doc_id: 744226
cord_uid: z4avm4zp

nan

This project was supported by an unconditional grant from FAES, with no role in the analysis, 32 decision to publish or preparation of the manuscript. The design, analysis, and writing of this 33 report are entirely the work and responsibility of the authors, and Dr. LAPLL had full access to 34 all data and final responsibility for the decision to submit this work for publication. 35

The database could be available upon reasonable request. 37

LAPLL reports grants, personal fees and non-financial support from AstraZeneca, personal fees 39 and non-financial support from GSK, grants and personal fees from TEVA, personal fees and 40 non-financial support from Novartis, personal fees and non-financial support from Chiesi, 41 personal fees from Sanofi, personal fees from Menarini, grants and personal fees from Esteve, 42 personal fees from ROVI, personal fees from MSD, personal fees from TECHDOW PHARMA, 43 non-financial support from FAES, outside the submitted work. The rest of the authors do not 44 report conflicts of interest related to the submitted work. 45

Author´s contributions to the study: 46 of data; drafting the work; final approval of the version to be published; agreement to be 48 accountable for all aspects of the study in ensuring that questions related to the accuracy or 49 integrity of any part of the work are appropriately investigated and resolved. Were principal study; drafting the work; analysis and interpretation of data; final approval of the version to be 54 published. RM: has made substantial contributions to acquisition of data; interpretation of 55 data; final approval of the version to be published. PPEY: has made substantial contributions to 56 acquisition of data; interpretation of data; final approval of the version to be published; AA: 57 has made substantial contributions to acquisition of data; interpretation of data; final approval 58 of the version to be published. RZ: has made substantial contributions to acquisition of data; 59 interpretation of data; final approval of the version to be published. CC: has made substantial 60 contributions to acquisition of data; interpretation of data; final approval of the version to be 61 published. AT: has made substantial contributions to acquisition of data; interpretation of 62 data; drafting the work; final approval of the version to be published. matched into 464 pairs. Clinical and laboratory characteristics in the cohort of patients 115 exposed and not exposed to corticosteroids, before and after PSM, are shown in Table   116 1. Patients receiving corticosteroids therapy were younger, less frequently male, had The database could be available upon reasonable request. 174 Ethics approval: 175 The study was approved by CEIm Hospital Universitario y Politécnico La Fe (Cód. 2020-176 122-1) and CEIm Autonómico de Galicia (Cod. 2020/239).. 

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis 192 on clinical outcomes

Corticosteroids Treatment of 195 Patients with Coronavirus Disease 2019: A Propensity Score Matching Study

Corticosteroid treatment has no effect on hospital mortality in COVID-19 199 patients

The use of 201 methylprednisolone in COVID-19 patients: A propensity score matched 202 retrospective cohort study

Mortality in Severe and Critical COVID-19 Patients in Wuhan

Effects of Corticosteroid 208 Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score

Low-to-moderate dose 211 corticosteroids treatment in hospitalized adults with COVID-19

Corticosteroid treatment in 214 severe COVID-19 patients with acute respiratory distress syndrome

Corticosteroids treatment 217 in severe patients with COVID-19: a propensity score matching study

Corticosteroid therapy for 220 coronavirus disease 2019-related acute respiratory distress syndrome: a cohort 221 study with propensity score analysis

R: A language and environment for statistical computing

R Foundation for Statistical Computing